Compare EXP & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | LNTH |
|---|---|---|
| Founded | 1963 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.5B |
| IPO Year | 1994 | 2014 |
| Metric | EXP | LNTH |
|---|---|---|
| Price | $169.38 | $99.85 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 10 |
| Target Price | ★ $195.50 | $106.99 |
| AVG Volume (30 Days) | 428.6K | ★ 868.0K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.29 | 2.91 |
| Revenue | ★ $495,023,000.00 | $343,374,000.00 |
| Revenue This Year | $0.74 | N/A |
| Revenue Next Year | $3.12 | $12.19 |
| P/E Ratio | $51.85 | ★ $34.36 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $160.02 | $50.16 |
| 52 Week High | $245.53 | $111.86 |
| Indicator | EXP | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 44.06 |
| Support Level | N/A | $98.81 |
| Resistance Level | $218.97 | $100.40 |
| Average True Range (ATR) | 4.02 | 0.34 |
| MACD | 0.77 | 0.05 |
| Stochastic Oscillator | 54.33 | 55.50 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.